Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Junshi Out-Licenses Partial China Marketing Rights for PD-1 to AstraZeneca

publication date: Mar 1, 2021

Shanghai's Junshi Bio out-licensed certain China marketing rights for its approved PD-1 to AstraZeneca. AstraZeneca will have rights to toripalimab for urothelial carcinoma and other "non-core" indications. According to Junshi, AZN has extensive networks in China, including county-level markets. Junshi has filed an NDA in China for approval of the PD-1 as a second line therapy for bladder cancer. Junshi will continue to market toripalimab for melanoma, its original indication, and will apparently take on other indications as well. More details....

Stock Symbols: (HK: 1877; SHA: 688180) (NYSE: AZN)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.